Pub Date : 2025-10-10DOI: 10.1016/j.bulcan.2025.08.005
Dominique Levêque
{"title":"Oral anticancer agents as generators of relevant pharmacokinetic interactions: An update","authors":"Dominique Levêque","doi":"10.1016/j.bulcan.2025.08.005","DOIUrl":"10.1016/j.bulcan.2025.08.005","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 12","pages":"Pages 1436-1437"},"PeriodicalIF":0.8,"publicationDate":"2025-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145276822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-10-08DOI: 10.1016/j.bulcan.2025.07.021
Eléa Janvier , Matthieu Delaye
{"title":"Nivolumab et ipilimumab – carcinome hépatocellulaire avancé et non résécable en première ligne de traitement","authors":"Eléa Janvier , Matthieu Delaye","doi":"10.1016/j.bulcan.2025.07.021","DOIUrl":"10.1016/j.bulcan.2025.07.021","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 12","pages":"Pages 1356-1357"},"PeriodicalIF":0.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Therapy-related myeloid neoplasms (t-MNs) include therapy-related acute myeloid leukemia (t-AML) and therapy-related myelodysplastic syndromes (t-MDS), arising from exposure to cytotoxic chemotherapy and/or radiation therapy used to treat prior malignancies. We conducted a retrospective study in a large cohort of patients at Gustave-Roussy Institute, over the period extending from January 1st, 1995 to June 30th, 2018. We used the 2010 ELN prognostic classifications for AML and or IPSS for MDS. In all, 404 patients with t-MN were referred to our institution, including 204 cases of t-AML and 200 cases of t-MDS. Based on the ELN 2010 classification 43%, 22% and 20% of t-AML were classified as adverse, intermediate (I/II) and favorable, respectively. Based on the IPSS classification, 72% of t-MDS were considered as intermediate-2/high and 28% as low/intermediate-1 risk. The median overall survival (OS) was 11.9 months for both t-AML and t-MDS (95% CI: 8.5–14.2 for t-AML and 9.3–14.1 for t-MDS), but long-term survival was mainly demonstrated in t-AML patients (5 years OS 24.6% [19–31.3] in t-AML vs. 10.6% [6.8–16.3] in t-MDS). In multivariate analysis for t-AML, intensive therapy (HR [95%CI]: 0.26 [0.15–0.46]), adverse ELN 2010 risk (1.57 [1.03–2.39]), cancer disease status (2.65 [1.53–4.57]) and performance status > 1 (2.69 [1.72–4.14]) were a powerful markers of OS. For t-MDS, only intermediate 2/high IPSS score (3.11 [2.06–4.79]) and Performance Status > 1 (3.13 [2.05–4.71]) remained independent markers of OS. Despite some benefit from intensive therapies in selected t-MN cases, survival remains limited, particularly when adverse disease features or active malignancies are present.
{"title":"Therapy related myeloid neoplasm, same but different?","authors":"Lina El Murr , Khalil Saleh , Florence Pasquier , Christophe Willekens , Alina Danu , Sylvain Pilorge , Nathalie Auger , Véronique Saada , Suzette Delaloge , Stéphane De Botton , Arnaud Pagès , Jean-Baptiste Micol","doi":"10.1016/j.bulcan.2025.08.003","DOIUrl":"10.1016/j.bulcan.2025.08.003","url":null,"abstract":"<div><div>Therapy-related myeloid neoplasms (t-MNs) include therapy-related acute myeloid leukemia (t-AML) and therapy-related myelodysplastic syndromes (t-MDS), arising from exposure to cytotoxic chemotherapy and/or radiation therapy used to treat prior malignancies. We conducted a retrospective study in a large cohort of patients at Gustave-Roussy Institute, over the period extending from January 1st, 1995 to June 30th, 2018. We used the 2010 ELN prognostic classifications for AML and or IPSS for MDS. In all, 404 patients with t-MN were referred to our institution, including 204 cases of t-AML and 200 cases of t-MDS. Based on the ELN 2010 classification 43%, 22% and 20% of t-AML were classified as adverse, intermediate (I/II) and favorable, respectively. Based on the IPSS classification, 72% of t-MDS were considered as intermediate-2/high and 28% as low/intermediate-1 risk. The median overall survival (OS) was 11.9 months for both t-AML and t-MDS (95% CI: 8.5–14.2 for t-AML and 9.3–14.1 for t-MDS), but long-term survival was mainly demonstrated in t-AML patients (5 years OS 24.6% [19–31.3] in t-AML vs. 10.6% [6.8–16.3] in t-MDS). In multivariate analysis for t-AML, intensive therapy (HR [95%CI]: 0.26 [0.15–0.46]), adverse ELN 2010 risk (1.57 [1.03–2.39]), cancer disease status (2.65 [1.53–4.57]) and performance status<!--> <!-->><!--> <!-->1 (2.69 [1.72–4.14]) were a powerful markers of OS. For t-MDS, only intermediate 2/high IPSS score (3.11 [2.06–4.79]) and Performance Status<!--> <!-->><!--> <!-->1 (3.13 [2.05–4.71]) remained independent markers of OS. Despite some benefit from intensive therapies in selected t-MN cases, survival remains limited, particularly when adverse disease features or active malignancies are present.</div></div>","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 12","pages":"Pages 1385-1393"},"PeriodicalIF":0.8,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145260130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-22DOI: 10.1016/j.bulcan.2025.07.025
Jean-Christophe Mino , Pauline Vaflard , Benjamin Derbez , Carole Bouleuc , Elisabeth Lucchi , Anne Brédart , Gisèle Chvetzoff , Sylvie Dolbeault
{"title":"Envisager la proportionnalité des traitements en phase avancée de la maladie : un enjeu structurant pour l’avenir de la cancérologie","authors":"Jean-Christophe Mino , Pauline Vaflard , Benjamin Derbez , Carole Bouleuc , Elisabeth Lucchi , Anne Brédart , Gisèle Chvetzoff , Sylvie Dolbeault","doi":"10.1016/j.bulcan.2025.07.025","DOIUrl":"10.1016/j.bulcan.2025.07.025","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1236-1239"},"PeriodicalIF":0.8,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133130","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Adhésion à l’hormonothérapie adjuvante chez les femmes jeunes atteintes d’un cancer du sein : un levier sous-exploité pour améliorer leur survie","authors":"Floriane Jochum , Élise Dumas , Florence Coussy , Paul Gougis , Anne-Sophie Hamy , Cherif Akladios","doi":"10.1016/j.bulcan.2025.07.024","DOIUrl":"10.1016/j.bulcan.2025.07.024","url":null,"abstract":"","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 11","pages":"Pages 1353-1354"},"PeriodicalIF":0.8,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-09-17DOI: 10.1016/j.bulcan.2025.07.014
Annaëlle Rousseaux , Camille Leglise , Lauriane Goldwirt , Kevin Beccaria , Nimrod Buchbinder , Julien Lejeune , Guy Leverger , Arnaud Petit , Pierre Simon Rohrlich , Stéphane Ducassou , Marion Strullu
<div><div>L’utilisation des réservoirs d’Ommaya pour l’administration intraventriculaire de chimiothérapie dans les leucémies aiguës pédiatriques reste hétérogène, bien qu’elle représente une alternative précieuse en cas d’échec ou d’impossibilité de ponction lombaire. Cette étude avait pour objectif d’évaluer les pratiques nationales et d’élaborer des recommandations harmonisées, sous l’égide du comité leucémies de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE). Un questionnaire national de 34 items a été diffusé auprès de 83 pédiatres hémato-oncologues du réseau SFCE explorant les indications, les modalités chirurgicales, les posologies, les pratiques au lit du patient et la gestion des complications. Trente-deux réponses provenant de 24 centres ont été analysées. La pose d’un réservoir d’Ommaya est principalement indiquée en cas de ponction lombaire non réalisable. En situation de méningite leucémique réfractaire ou récidivante, les données pharmacocinétiques justifient son usage, avec une meilleure diffusion du méthotrexate dans le liquide cérébro-spinal. Une réduction de 50 % des doses intrathécales (méthotrexate, cytarabine, hydrocortisone) est recommandée, en raison d’une efficacité équivalente et d’une meilleure tolérance. Le respect strict des mesures d’asepsie est crucial pour limiter les infections (5–8 %). En cas d’infection, un retrait temporaire du dispositif est préconisé. Le réservoir d’Ommaya constitue une alternative efficace et sûre à la voie lombaire dans des situations sélectionnées. Ces recommandations visent à homogénéiser les pratiques et à renforcer la sécurité des soins.</div></div><div><div>The use of Ommaya reservoirs for intraventricular chemotherapy in pediatric acute leukemias remains heterogeneous, despite being a valuable alternative when lumbar puncture (LP) is unsuccessful or contraindicated. This study aimed to evaluate national practices and develop harmonized recommendations under the auspices of the French Society for the Fight Against Childhood and Adolescent Cancers and Leukemias (SFCE) Committee. A national 34-item questionnaire was distributed to 83 pediatric hemato-oncologists within the SFCE network, covering indications, surgical procedures, dosing, bedside practices, and complication management. Thirty-two responses from 24 centers were analyzed. The primary indication for Ommaya reservoir placement was the inability to perform LP. In cases of refractory or relapsed leukemic meningitis, pharmacokinetic data support its use due to improved methotrexate distribution in cerebrospinal fluid (CSF). A 50% dose reduction for intrathecal medications (methotrexate, cytarabine, hydrocortisone) is recommended, ensuring equivalent efficacy and improved tolerance. Strict aseptic techniques are essential to minimize infection risk (5–8%). In the event of infection, temporary removal of the device is advised. The Ommaya reservoir represents an effective and s
{"title":"Utilisation des réservoirs d’Ommaya au cours du traitement des leucémies aiguës pédiatriques : recommandations du comité Leucémies de la Société française de lutte contre les cancers et leucémies de l’enfant et de l’adolescent (SFCE)","authors":"Annaëlle Rousseaux , Camille Leglise , Lauriane Goldwirt , Kevin Beccaria , Nimrod Buchbinder , Julien Lejeune , Guy Leverger , Arnaud Petit , Pierre Simon Rohrlich , Stéphane Ducassou , Marion Strullu","doi":"10.1016/j.bulcan.2025.07.014","DOIUrl":"10.1016/j.bulcan.2025.07.014","url":null,"abstract":"<div><div>L’utilisation des réservoirs d’Ommaya pour l’administration intraventriculaire de chimiothérapie dans les leucémies aiguës pédiatriques reste hétérogène, bien qu’elle représente une alternative précieuse en cas d’échec ou d’impossibilité de ponction lombaire. Cette étude avait pour objectif d’évaluer les pratiques nationales et d’élaborer des recommandations harmonisées, sous l’égide du comité leucémies de la Société française de lutte contre les cancers et les leucémies de l’enfant et de l’adolescent (SFCE). Un questionnaire national de 34 items a été diffusé auprès de 83 pédiatres hémato-oncologues du réseau SFCE explorant les indications, les modalités chirurgicales, les posologies, les pratiques au lit du patient et la gestion des complications. Trente-deux réponses provenant de 24 centres ont été analysées. La pose d’un réservoir d’Ommaya est principalement indiquée en cas de ponction lombaire non réalisable. En situation de méningite leucémique réfractaire ou récidivante, les données pharmacocinétiques justifient son usage, avec une meilleure diffusion du méthotrexate dans le liquide cérébro-spinal. Une réduction de 50 % des doses intrathécales (méthotrexate, cytarabine, hydrocortisone) est recommandée, en raison d’une efficacité équivalente et d’une meilleure tolérance. Le respect strict des mesures d’asepsie est crucial pour limiter les infections (5–8 %). En cas d’infection, un retrait temporaire du dispositif est préconisé. Le réservoir d’Ommaya constitue une alternative efficace et sûre à la voie lombaire dans des situations sélectionnées. Ces recommandations visent à homogénéiser les pratiques et à renforcer la sécurité des soins.</div></div><div><div>The use of Ommaya reservoirs for intraventricular chemotherapy in pediatric acute leukemias remains heterogeneous, despite being a valuable alternative when lumbar puncture (LP) is unsuccessful or contraindicated. This study aimed to evaluate national practices and develop harmonized recommendations under the auspices of the French Society for the Fight Against Childhood and Adolescent Cancers and Leukemias (SFCE) Committee. A national 34-item questionnaire was distributed to 83 pediatric hemato-oncologists within the SFCE network, covering indications, surgical procedures, dosing, bedside practices, and complication management. Thirty-two responses from 24 centers were analyzed. The primary indication for Ommaya reservoir placement was the inability to perform LP. In cases of refractory or relapsed leukemic meningitis, pharmacokinetic data support its use due to improved methotrexate distribution in cerebrospinal fluid (CSF). A 50% dose reduction for intrathecal medications (methotrexate, cytarabine, hydrocortisone) is recommended, ensuring equivalent efficacy and improved tolerance. Strict aseptic techniques are essential to minimize infection risk (5–8%). In the event of infection, temporary removal of the device is advised. The Ommaya reservoir represents an effective and s","PeriodicalId":9365,"journal":{"name":"Bulletin Du Cancer","volume":"112 12","pages":"Pages 1438-1446"},"PeriodicalIF":0.8,"publicationDate":"2025-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145088544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号